ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1802

The Utility of Dual-energy Computed Tomography in Gout Patients During Urate Lowering Therapy
Abstract Number: 1239

The Utility of Dual-Energy Computed Tomography in the Diagnosis of Gout
Abstract Number: 1551

The Utility of Imaging Studies (MRA and CTA) in Long-Term Monitoring for Patients with Takayasu Arteritis
Abstract Number: 2028

The Value of FDG-PET/CT in the Detection of Lymphomas Associated with Primary Sjögren’s Syndrome
Abstract Number: 0210

Themes in Patients’ Discordance with Provider’s Rheumatoid Arthritis Treatment Goals Relate to Patient Age, Gender, and Ethnicity
Abstract Number: 0820

Therapeutic Practices and Outcomes of Chronic Sarcoidosis Arthropathy in the United States: A Nationwide Registry Study
Abstract Number: 1795

Therapeutic Strategies for Patients with Chronic Manifestations of Calcium Pyrophosphate Deposition Disease
Abstract Number: 0344

Therapeutic Thresholds of Hydroxychloroquine Blood Levels: Physiologic and Social Determinants of Low Hydroxychloroquine Blood Levels
Abstract Number: 0130

Three Chinese Pedigrees of A20 Haploinsufficiency
Abstract Number: 2275

Three Dose SARS-CoV-2 Vaccination Is Associated with Reduced Risk of Breakthrough COVID-19 During Omicron Wave in Patients with Autoimmune Diseases
Abstract Number: 0504

Three-dimensional Ground Reaction Force Symmetry Metrics Largely Fail to Explain Cartilage Worsening in the Contralateral Knee in Persons with Unilateral Knee Osteoarthritis: The Multicenter Osteoarthritis Study
Abstract Number: 0671

Thrombocytopenia and Autoimmune Hemolytic Anemia in Antiphospholipid Antibody-positive Patients: Descriptive Analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking (APS ACTION) Clinical Database and Repository (“Registry”)
Abstract Number: 1419

Time to Discontinuation and Effectiveness with Baricitinib in Rheumatoid Arthritis: 12-Month European Data from a Multinational, Prospective, Observational Study
Abstract Number: 1430

Time to First Remission and Prevalence of Sustained Remission After Etanercept Biosimilar (ETA-B) or Originator (ETA-O) Initiation in Rheumatoid Arthritis
Abstract Number: 1266

Time-course Ultrasonography to Predict Flare After Discontinuation of Biologics in Patients with Rheumatoid Arthritis Achieving Stringent Remission

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].